Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Crying in their beer

At first blush, the five U.S. IPOs that have priced in the last three weeks have not lived up to their expectations. The group has raised $273 million, but in doing so has left $203 million on the table based on their stated targets. Indeed, the pessimists will note that the average take by the recent group is down 12 percent to $54.6 million from the $62.1 million average in the U.S. IPO class of '99.

But in the current world of wild expectations, they may not have noticed that the size of the latest deals nearly doubles the average for each year between 1994 and 1998 (see "Half Full or Half Empty?").And the recent group's average will go up, as only cancer play Praecis (PRCS) has sold its overallotment. Rounding out the group is pharmacogenomics play Orchid (ORCH); gene function and bioinformatics play Paradigm (PDGM); Genomic Solutions (GNSL), a manufacturer and marketer of genomic and proteomic

Read the full 1562 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE